RU2015143207A - COMPOSITIONS AND METHODS OF IMMUNOTHERAPY - Google Patents
COMPOSITIONS AND METHODS OF IMMUNOTHERAPY Download PDFInfo
- Publication number
- RU2015143207A RU2015143207A RU2015143207A RU2015143207A RU2015143207A RU 2015143207 A RU2015143207 A RU 2015143207A RU 2015143207 A RU2015143207 A RU 2015143207A RU 2015143207 A RU2015143207 A RU 2015143207A RU 2015143207 A RU2015143207 A RU 2015143207A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- cell
- receptor
- polypeptide
- chimeric
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 42
- 102000036639 antigens Human genes 0.000 claims 42
- 108091007433 antigens Proteins 0.000 claims 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 22
- 230000002401 inhibitory effect Effects 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 13
- 230000003834 intracellular effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- -1 EGP-40 Proteins 0.000 claims 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 101150030213 Lag3 gene Proteins 0.000 claims 4
- 102100026742 Opioid-binding protein/cell adhesion molecule Human genes 0.000 claims 4
- 101710096745 Opioid-binding protein/cell adhesion molecule Proteins 0.000 claims 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 102000000905 Cadherin Human genes 0.000 claims 3
- 108050007957 Cadherin Proteins 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 102000011782 Keratins Human genes 0.000 claims 3
- 108010076876 Keratins Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000031146 intracellular signal transduction Effects 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 101000971151 Homo sapiens Protein BANP Proteins 0.000 claims 2
- 102100021567 Protein BANP Human genes 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 208000020615 rectal carcinoma Diseases 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000011057 Breast sarcoma Diseases 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 claims 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102100032816 Integrin alpha-6 Human genes 0.000 claims 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100040120 Prominin-1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100035721 Syndecan-1 Human genes 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 230000005965 immune activity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001128—CD44 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46431—Contraceptive or sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464495—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Claims (51)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361802118P | 2013-03-15 | 2013-03-15 | |
US61/802,118 | 2013-03-15 | ||
PCT/US2014/030671 WO2015142314A1 (en) | 2013-03-15 | 2014-03-17 | Compositions and methods for immunotherapy |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2015143207A true RU2015143207A (en) | 2017-04-20 |
RU2015143207A3 RU2015143207A3 (en) | 2018-05-08 |
RU2729118C2 RU2729118C2 (en) | 2020-08-04 |
Family
ID=50513511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015143207A RU2729118C2 (en) | 2013-03-15 | 2014-03-17 | Compositions and methods of immunotherapy |
Country Status (18)
Country | Link |
---|---|
US (2) | US11267901B2 (en) |
EP (2) | EP4098275A1 (en) |
JP (5) | JP6857028B2 (en) |
KR (3) | KR102466666B1 (en) |
CN (1) | CN105246504A (en) |
AU (2) | AU2014386824B2 (en) |
BR (1) | BR112015023679A2 (en) |
CA (1) | CA2904265C (en) |
HK (1) | HK1220387A1 (en) |
IL (2) | IL300508A (en) |
MX (2) | MX2015013104A (en) |
MY (1) | MY195733A (en) |
NZ (1) | NZ712693A (en) |
PH (1) | PH12015502271B1 (en) |
RU (1) | RU2729118C2 (en) |
SA (1) | SA515361180B1 (en) |
SG (1) | SG11201507688VA (en) |
WO (1) | WO2015142314A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2808254C2 (en) * | 2018-08-10 | 2023-11-28 | Сангамо Терапьютикс Франс | New chimeric antigen receptor constructs containing tnfr2 domains |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
KR102466666B1 (en) * | 2013-03-15 | 2022-11-15 | 메모리얼 슬로안 케터링 캔서 센터 | Compositions and methods for immunotherapy |
DK2981607T3 (en) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | EFFICIENT GENERATION OF TUMOR-TARGETED T-CELLS DERIVED FROM PLURIPOTENT STEM CELLS |
KR101962524B1 (en) | 2013-11-21 | 2019-07-17 | 유씨엘 비즈니스 피엘씨 | Cell |
SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
US11072644B2 (en) | 2014-11-12 | 2021-07-27 | Allogene Therapeutics, Inc. | Inhibitory chimeric antigen receptors |
WO2016090190A1 (en) | 2014-12-03 | 2016-06-09 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
ES2976197T3 (en) | 2014-12-24 | 2024-07-26 | Autolus Ltd | Cell |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
WO2016179319A1 (en) * | 2015-05-04 | 2016-11-10 | Cellerant Therapeutics, Inc. | Chimeric antigen receptors with ctla4 signal transduction domains |
PL3298033T5 (en) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Compositions and medical uses for tcr reprogramming using fusion proteins |
GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
EP3344284A1 (en) | 2015-09-04 | 2018-07-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
EP3371314B1 (en) | 2015-11-04 | 2023-07-05 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
JP7534070B2 (en) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス,インコーポレイテッド | Methods and compositions for inducing hematopoietic cell differentiation - Patents.com |
AU2016366226B2 (en) | 2015-12-09 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
WO2017132279A1 (en) | 2016-01-25 | 2017-08-03 | Genentech, Inc. | Methods for assaying t-cell dependent bispecific antibodies |
CN105567640A (en) * | 2016-01-27 | 2016-05-11 | 苏州佰通生物科技有限公司 | Chimeric antigen receptor adipose-derived stem cell and preparation method thereof |
WO2017173403A1 (en) * | 2016-03-31 | 2017-10-05 | University Of Southern California | A highly sensitive and specific luciferase based reporter assay for antigen detection |
EP4201422A1 (en) | 2016-04-22 | 2023-06-28 | CRAGE medical Co., Limited | Compositions and methods of cellular immunotherapy |
US11478508B2 (en) * | 2016-05-25 | 2022-10-25 | The Council Of The Queensland Institute Of Medical Research | Methods of immunotherapy |
CN105950561A (en) * | 2016-05-26 | 2016-09-21 | 江苏杰晟生物科技有限公司 | Products and preparation method of double chimeric antigen receptor gene modified T lymphocyte targeting breast cancer stem cells |
EP4011381A1 (en) * | 2016-06-03 | 2022-06-15 | Memorial Sloan-Kettering Cancer Center | Adoptive cell therapies as early treatment options |
CN109715668A (en) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | For using fusion protein to carry out the composition and method of TCR reprogramming |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
CN109863242A (en) | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | For treating the immunocyte composition and application method of virus infection and other infection |
EP3519564B1 (en) * | 2016-09-28 | 2023-11-15 | Gavish-Galilee Bio Applications Ltd | A universal platform for car therapy targeting a novel antigenic signature of cancer |
ES2875959T3 (en) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Compositions and methods for T-cell receptor reprogramming using fusion proteins |
CN107988164B (en) | 2016-10-26 | 2020-07-07 | 阿思科力(苏州)生物科技有限公司 | PD-1CAR NK-92 cell and preparation method and application thereof |
EP3315511A1 (en) * | 2016-10-29 | 2018-05-02 | Miltenyi Biotec GmbH | Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CN108204958A (en) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | binding assay |
WO2018115146A1 (en) * | 2016-12-21 | 2018-06-28 | Danmarks Tekniske Universitet | Antigen presenting scaffolds for immune-cell manipulation |
CN110121505B (en) * | 2016-12-28 | 2023-08-01 | 株式会社绿十字细胞治疗 | Chimeric antigen receptor and natural killer cell expressing same |
US20200010803A1 (en) * | 2017-03-08 | 2020-01-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
BR112019020001A2 (en) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | stimulating cell lines for ex vivo expansion and activation of natural killer cells |
WO2018183385A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
CN107034237B (en) * | 2017-03-31 | 2018-10-16 | 北京呈诺医学科技有限公司 | A kind of CAR-NK cells and the preparation method and application thereof |
KR20240059648A (en) * | 2017-04-19 | 2024-05-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Immune cells expressing engineered antigen receptors |
GB201707779D0 (en) * | 2017-05-15 | 2017-06-28 | Autolus Ltd | Cell |
CA3064597A1 (en) * | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods related to toxicity associated with cell therapy |
EP3688155B1 (en) * | 2017-09-28 | 2023-01-04 | Immpact-Bio Ltd. | A universal platform for preparing an inhibitory chimeric antigen receptor (icar) |
CN109593721B (en) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技(上海)有限公司 | Engineered immune cells targeting human mesothelin with suicide gene switch |
GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
EP3720883B1 (en) | 2017-12-05 | 2023-04-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
KR20200106051A (en) * | 2017-12-29 | 2020-09-10 | 메모리얼 슬로안 케터링 캔서 센터 | Improved chimeric antigen receptor and uses thereof |
CN109321530B (en) * | 2018-02-12 | 2021-03-12 | 华东师范大学 | Safe chimeric antigen receptor T cell and application thereof |
CN111954527A (en) * | 2018-04-09 | 2020-11-17 | 梅约医学教育与研究基金会 | Methods and materials for treating graft versus host disease |
CN110526984A (en) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | It is a kind of to target the Chimeric antigen receptor of PSMA, Chimeric antigen receptor T cell and its preparation method and application |
CN110526976A (en) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | It is a kind of to target the single-chain antibody of PSMA, Chimeric antigen receptor T cell and its preparation method and application |
WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
TW202016144A (en) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | Compositions including cd3 antigen binding fragments and uses thereof |
WO2020069508A1 (en) * | 2018-09-28 | 2020-04-02 | Memorial Sloan-Kettering Cancer Center | Immunoresponsive cells expressing dominant negative fas and uses thereof |
WO2020065406A2 (en) | 2018-09-28 | 2020-04-02 | Immpact-Bio Ltd. | Methods for identifying activating antigen receptor (acar)/inhibitory chimeric antigen receptor (icar) pairs for use in cancer therapies |
CN109517799B (en) * | 2018-11-30 | 2022-07-26 | 北京美康基免生物科技有限公司 | CD19 and CD22 based double chimeric antigen receptor gene modified immune cell and application thereof |
CA3124444A1 (en) | 2019-01-23 | 2020-07-30 | Miltenyi Biotec B.V. & Co. KG | A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
BR112021017537A2 (en) | 2019-03-05 | 2021-12-14 | Nkarta Inc | Chimeric antigen receptors targeting cd19 and their uses in immunotherapy |
CN114007642A (en) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | Chimeric receptors and methods of use thereof |
CN110592014A (en) * | 2019-08-14 | 2019-12-20 | 广东美赛尔细胞生物科技有限公司 | Method for continuously removing feeder cells in vitro and in vivo without irradiation in NK cell therapy |
EP4045066A4 (en) * | 2019-10-18 | 2024-03-20 | Board of Regents, The University of Texas System | Hla-restricted vcx/y peptides and t cell receptors and use thereof |
EP4073103A1 (en) | 2019-12-11 | 2022-10-19 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
WO2021156277A1 (en) | 2020-02-04 | 2021-08-12 | Miltenyi Biotec B.V. & Co. KG | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens |
CN115397845A (en) * | 2020-02-20 | 2022-11-25 | 森迪生物科学公司 | Inhibitory chimeric receptor architectures |
CN111249314B (en) * | 2020-03-03 | 2022-03-29 | 深圳未知君生物科技有限公司 | Role of human symbiotic flora in improving tumor immunotherapy response |
JP2023525910A (en) * | 2020-05-20 | 2023-06-19 | ミルテニイ ビオテック ベー.ファー. ウント コー.カーゲー | Compositions and methods for treating cancers expressing CD90 and CD326 |
US20210371490A1 (en) | 2020-05-28 | 2021-12-02 | Miltenyi Biotec B.V. & Co. KG | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains |
WO2022007784A1 (en) * | 2020-07-06 | 2022-01-13 | Nanjing Legend Biotech Co., Ltd. | Methods of reducing graft rejection of allogeneic cell therapy |
WO2022015955A1 (en) | 2020-07-16 | 2022-01-20 | Umoja Biopharma, Inc. | Gated adapter targeting receptor |
WO2022037323A1 (en) * | 2020-08-19 | 2022-02-24 | 上海易慕峰生物科技有限公司 | Humanized antibody, chimeric antigen receptor, nucleic acid, vector, cell and use |
JP2023538115A (en) | 2020-08-20 | 2023-09-06 | エー2 バイオセラピューティクス, インコーポレイテッド | Compositions and methods for treating CEACAM-positive cancers |
RS65802B1 (en) | 2020-08-20 | 2024-08-30 | A2 Biotherapeutics Inc | Compositions and methods for treating egfr positive cancers |
CA3188862A1 (en) | 2020-08-20 | 2022-02-24 | Carl Alexander Kamb | Compositions and methods for treating mesothelin positive cancers |
US20220090013A1 (en) * | 2020-09-21 | 2022-03-24 | A2 Biotherapeutics, Inc. | Engineering immune cells based on antigen levels |
US20230405047A1 (en) | 2020-11-09 | 2023-12-21 | Miltenyi Biotec B.V. & Co. KG | Methods and compositions for eliminating engineered immune cells |
CN114569708B (en) * | 2020-12-02 | 2023-07-04 | 四川大学华西医院 | Application of NKG2D CAR-immunocyte in anti-aging |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
EP4255454A2 (en) * | 2020-12-07 | 2023-10-11 | The Johns Hopkins University | Methods of nk cell engineering to enhance tumor targeting |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
CA3207958A1 (en) | 2021-02-16 | 2022-08-25 | Julyun OH | Compositions and methods for treating her2 positive cancers |
AU2022245215A1 (en) * | 2021-03-22 | 2023-10-12 | Memorial Hospital For Cancer And Allied Diseases | Cd38 chimeric co-stimulating receptor and uses thereof |
EP4413031A1 (en) | 2021-10-06 | 2024-08-14 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
WO2023109901A1 (en) | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies and methods of use |
CN118488965A (en) | 2021-12-17 | 2024-08-13 | 上海复宏汉霖生物技术股份有限公司 | Anti-OX 40 antibodies, multispecific antibodies, and methods of use thereof |
AU2023240941A1 (en) | 2022-03-25 | 2024-09-19 | Shanghai Henlius Biologics Co., Ltd. | Anti-msln antibodies and methods of use |
WO2024078995A1 (en) | 2022-10-15 | 2024-04-18 | Miltenyi Biotec B.V. & Co. KG | Transduction of gammadelta t cells with pseudotyped retroviral vectors |
CN116785458A (en) * | 2023-02-14 | 2023-09-22 | 青岛大学 | Application of cynoglossus semilaevis disease-resistant protein SHP-1 gene |
CN116376844B (en) * | 2023-05-31 | 2023-08-11 | 四川大学华西医院 | HER2 positive tumor targeting CAR-T containing SHP2 SH2 domain, preparation method and application |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
WO2008038587A1 (en) | 2006-09-25 | 2008-04-03 | National University Corporation Nagoya University | Cd20-negatively converted b cell malignant lymphocyte cell line and utilization of the same |
WO2008095141A2 (en) * | 2007-01-31 | 2008-08-07 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
DK2537416T3 (en) * | 2007-03-30 | 2015-01-05 | Sloan Kettering Inst Cancer | Constitutive expression of costimulatory ligands ON adoptively transferred T-LYMPHOCYTES |
DK2649086T3 (en) | 2010-12-09 | 2017-09-18 | Univ Pennsylvania | USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER |
US10981969B2 (en) * | 2011-07-29 | 2021-04-20 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CA2904014C (en) | 2013-02-06 | 2021-06-15 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
BR112015020516A2 (en) * | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | immunotherapy compositions and methods |
KR102466666B1 (en) * | 2013-03-15 | 2022-11-15 | 메모리얼 슬로안 케터링 캔서 센터 | Compositions and methods for immunotherapy |
WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
-
2014
- 2014-03-17 KR KR1020227002101A patent/KR102466666B1/en active IP Right Grant
- 2014-03-17 EP EP21213658.4A patent/EP4098275A1/en active Pending
- 2014-03-17 RU RU2015143207A patent/RU2729118C2/en active
- 2014-03-17 WO PCT/US2014/030671 patent/WO2015142314A1/en active Application Filing
- 2014-03-17 NZ NZ712693A patent/NZ712693A/en unknown
- 2014-03-17 AU AU2014386824A patent/AU2014386824B2/en active Active
- 2014-03-17 IL IL300508A patent/IL300508A/en unknown
- 2014-03-17 CN CN201480027699.9A patent/CN105246504A/en active Pending
- 2014-03-17 JP JP2016515328A patent/JP6857028B2/en active Active
- 2014-03-17 IL IL311390A patent/IL311390A/en unknown
- 2014-03-17 CA CA2904265A patent/CA2904265C/en active Active
- 2014-03-17 KR KR1020157029137A patent/KR20150128997A/en not_active IP Right Cessation
- 2014-03-17 MX MX2015013104A patent/MX2015013104A/en unknown
- 2014-03-17 SG SG11201507688VA patent/SG11201507688VA/en unknown
- 2014-03-17 KR KR1020227039192A patent/KR20220156663A/en active Application Filing
- 2014-03-17 BR BR112015023679A patent/BR112015023679A2/en not_active Application Discontinuation
- 2014-03-17 MY MYPI2015002377A patent/MY195733A/en unknown
- 2014-03-17 EP EP14718296.8A patent/EP2968492B1/en active Active
-
2015
- 2015-09-11 US US14/851,983 patent/US11267901B2/en active Active
- 2015-09-15 SA SA515361180A patent/SA515361180B1/en unknown
- 2015-09-15 PH PH12015502271A patent/PH12015502271B1/en unknown
- 2015-09-15 MX MX2019014008A patent/MX2019014008A/en unknown
-
2016
- 2016-07-19 HK HK16108530.2A patent/HK1220387A1/en unknown
-
2018
- 2018-09-19 JP JP2018174681A patent/JP2018196396A/en not_active Withdrawn
-
2019
- 2019-08-06 AU AU2019213338A patent/AU2019213338A1/en not_active Abandoned
-
2020
- 2020-04-24 JP JP2020077143A patent/JP7076493B2/en active Active
-
2021
- 2021-01-07 JP JP2021001277A patent/JP2021052800A/en not_active Withdrawn
-
2022
- 2022-01-24 US US17/583,117 patent/US20220162340A1/en active Pending
- 2022-10-19 JP JP2022167507A patent/JP2022186837A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2808254C2 (en) * | 2018-08-10 | 2023-11-28 | Сангамо Терапьютикс Франс | New chimeric antigen receptor constructs containing tnfr2 domains |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015143207A (en) | COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | |
JP2020114255A5 (en) | ||
JP2017503472A5 (en) | ||
RU2015116901A (en) | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | |
RU2015140811A (en) | COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | |
Zhukovsky et al. | Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection | |
Hettich et al. | Checkpoint antibodies but not T cell–recruiting diabodies effectively synergize with TIL-inducing γ-irradiation | |
Beavis et al. | Reprogramming the tumor microenvironment to enhance adoptive cellular therapy | |
Blank et al. | Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro | |
Esmaeilzadeh et al. | Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthma | |
Ruella et al. | Adoptive immunotherapy for cancer | |
Kershaw et al. | Gene-engineered T cells for cancer therapy | |
Feldmann et al. | Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells | |
Tuve et al. | Combination of tumor Site–Located CTL-Associated antigen-4 blockade and systemic regulatory T-cell depletion induces Tumor-Destructive immune responses | |
JP2015535689A5 (en) | ||
JP2022116230A5 (en) | ||
JP2021505131A5 (en) | ||
RU2017121115A (en) | GENETICALLY MODIFIED T-CELL DELTA GAMMA | |
Leblay et al. | Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities | |
EA202091982A1 (en) | Chimeric antigenic receptor to the receptor of IL-13 ALPHA 2 (IL13R2) for tumor-specific T-cell immunotherapy | |
PH12015502479B1 (en) | Cd19 specific chimeric antigen receptor and uses thereof | |
JP2017531687A5 (en) | ||
Lum et al. | CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma | |
JP2016510597A5 (en) | ||
RU2013147157A (en) | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY |